[go: up one dir, main page]

GR3035196T3 - Method for treating multiple sclerosis - Google Patents

Method for treating multiple sclerosis

Info

Publication number
GR3035196T3
GR3035196T3 GR20010400014T GR20010400014T GR3035196T3 GR 3035196 T3 GR3035196 T3 GR 3035196T3 GR 20010400014 T GR20010400014 T GR 20010400014T GR 20010400014 T GR20010400014 T GR 20010400014T GR 3035196 T3 GR3035196 T3 GR 3035196T3
Authority
GR
Greece
Prior art keywords
necrosis factor
tumour necrosis
multiple sclerosis
treating multiple
factor receptor
Prior art date
Application number
GR20010400014T
Other languages
English (en)
Inventor
John Leslie Turk
David Baker
Marc Feldmann
Original Assignee
Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Inst Of Rheumatology filed Critical Kennedy Inst Of Rheumatology
Publication of GR3035196T3 publication Critical patent/GR3035196T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Transplanting Machines (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GR20010400014T 1993-07-30 2001-01-10 Method for treating multiple sclerosis GR3035196T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001614 WO1995003827A1 (en) 1993-07-30 1993-07-30 Method for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
GR3035196T3 true GR3035196T3 (en) 2001-04-30

Family

ID=10729416

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400014T GR3035196T3 (en) 1993-07-30 2001-01-10 Method for treating multiple sclerosis

Country Status (11)

Country Link
US (1) US5958409A (el)
EP (2) EP1004312A1 (el)
JP (1) JPH09509646A (el)
AT (1) ATE196849T1 (el)
AU (1) AU4719093A (el)
DE (1) DE69329558T2 (el)
DK (1) DK0710121T3 (el)
ES (1) ES2153384T3 (el)
GR (1) GR3035196T3 (el)
PT (1) PT710121E (el)
WO (1) WO1995003827A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
DK0839046T3 (da) 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
CN1684708A (zh) * 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
EP1401484A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
CA2635445A1 (en) * 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE4202665A1 (de) * 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
DE69329558D1 (de) 2000-11-16
PT710121E (pt) 2001-04-30
EP1004312A1 (en) 2000-05-31
EP0710121A1 (en) 1996-05-08
US5958409A (en) 1999-09-28
ATE196849T1 (de) 2000-10-15
DK0710121T3 (da) 2001-02-05
WO1995003827A1 (en) 1995-02-09
ES2153384T3 (es) 2001-03-01
JPH09509646A (ja) 1997-09-30
EP0710121B1 (en) 2000-10-11
AU4719093A (en) 1995-02-28
DE69329558T2 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
GR3035196T3 (en) Method for treating multiple sclerosis
EP0620739A4 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
TW224053B (el)
JPS57193412A (en) Prevention of prostatic hyperplasia and therapeutical drug
AU7935487A (en) Immunotoxin therapy of allergy
IE830934L (en) 1,8-diaza-and 1,5,8-triazanaphthalene derivatives
ZA936799B (en) Method for treating symptoms associated with premenstrual syndrome by administering vitamin D or A combination of calcium and vitamin D
IE882628L (en) Substituted 2-phenyl-4-quinoline carboxylic acids
AU3236093A (en) The use of ob-101 to treat inflammation
AU3235693A (en) The use of ob-104 to treat inflammation
AU4530989A (en) Pharmaceutical composition for the treatment of cerebral edema
EP0325129A3 (en) Disubstituted pyridines
AU8634291A (en) Process and device for the manufacture of high-pressure laminates
GB2271509B (en) Antivenom immunesera
NO961226L (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
CA2002144A1 (en) Method of preventing or reducing eosinophilia
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
AU569354B2 (en) (-)-1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane
AU7770991A (en) Method and composition for the treatment of cancer
BG102087A (en) The use of pyrrolidine derivatives for the treatment of alcoholism
AU642772B2 (en) Inhibitors for the formation of tumor necrosis factor, processes for the preparation thereof and the use thereof
AU7719491A (en) Therapeutic compound
HUT59307A (en) Process for producing pharmaceutical compositions comprising zofenopril and suitable for treating arthritis
AU3539189A (en) Prophylactic and therapeutic methods for treating edema with phallotoxins